Screener
Idexx Laboratories IDXX Impairment Charges
Impairment Charges at other companies
Other financials
Where this comes from
Reported directly by Idexx Laboratories in its filing.
Tagged under the XBRL concept us-gaap:AssetImpairmentCharges.
The source filing: Idexx Laboratories’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:14 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000874716-26-000076
| Line item | For the Three Months Ended March 31, 2026 | For the Three Months Ended March 31, 2025 |
|---|---|---|
| Net income | $278,446 | $242,677 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation and amortization | 37,683 | 34,063 |
| Impairment charge | 5,000 | — |
| Provision for credit losses | 3,942 | 2,890 |
| Deferred income taxes | 13,890 | 3,948 |
| Share-based compensation expense | 16,340 | 14,615 |
| Other | 695 | 456 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Idexx Laboratories's impairment charges?
- Idexx Laboratories (IDXX) reported impairment charges of $5M in Q1 2026.
- What does impairment charges mean?
- Non-cash asset impairment charges added back in the operating cash flow reconciliation since they don't represent cash outflows.
Ask your AI about Idexx Laboratories's impairment charges.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude